Question

Mohammad Yasin

Labour — Bedford

To ask the Secretary of State for Health and Social Care, what assessment he has made of the clinical and cost effectiveness of first-line use of encorafenib in combination with cetuximab and chemotherapy for patients with BRAF V600E-mutant metastatic col